Details of the Drug Combination

General Information of Drug Combination (ID: DC7TY8V)

• Drug Combination Name: Phensuximide + Cisatracurium
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Phensuximide (DMFGLXB): Small molecular drug
  Cisatracurium (DMUZPJ5): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 10.64
  Bliss Independence Score: 10.64
  Loewe Additivity Score: 30.69
  LHighest Single Agent (HSA) Score: 30.72

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Phensuximide

Disease Entry	ICD 11	Status	REF
Absence epilepsy	N.A.	Approved	[2]
Epilepsy	8A60-8A68	Approved	[2]
Seizure disorder	8A6Z	Approved	[3]

Indication(s) of Cisatracurium

Disease Entry	ICD 11	Status	REF
Muscle spasm	MB47.3	Approved	[4]

Cisatracurium Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Cholinergic receptor unspecific (CHR)	TTUPDWN	NOUNIPROTAC	Antagonist	[5]
Neuronal acetylcholine receptor alpha-2 (CHRNA2)	TTF4E0J	ACHA2_HUMAN	Antagonist	[6]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Phensuximide FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7612).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
• [6] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.